Effect of clot removal on cerebrovascular contraction after subarachnoid hemorrhage in the monkey: pharmacological study.
Clot removal at early surgery has been reported to be clinically effective for the prevention of cerebral vasospasm following subarachnoid hemorrhage (SAH) due to rupture of an intracranial aneurysm. We examined the most efficacious timing of mechanical clot removal on pharmacological responses in a monkey SAH model. Cynomolgus monkeys (Macaca fascicularis) were randomized into five groups: sham-operated, clot removal in which the clot was removed 48, 72, or 96 h after SAH, and clot groups. An autologous blood clot was placed around the bilateral major cerebral arteries after craniectomy to mimic the hemorrhage. Seven days after the SAH, proximal and successively distal parts of the middle cerebral arteries were cut into rings for isometric tension measurement. The contractile responses to potassium chloride, 5-hydroxytryptamine, norepinephrine, adenosine triphosphate, prostaglandin F20, and hemoglobin were greater in the proximal parts than in the distal parts in each group. Compared with the sham-operated group, the responses of the clot-removal and clot groups to the drugs were progressively attenuated. The maximum responses to 5-hydroxytryptamine in the proximal parts and to adenosine triphosphate in the distal parts started to decrease, significantly, in the clot-removal group 48 h after SAH, while most of the responses to the other agonists began to decrease in the clot-removal groups later than 72 h after SAH. These results suggest that the attenuation of cerebrovascular contractile responses 7 days after SAH is pharmacologically inevitable, even if the clot is removed as early as 48 h after the SAH. Clot removal may thus be recommended within 48h after SAH to ameliorate the severity of cerebral vasospasm following SAH.
Tsuji
T
T
Department of Neurosurgery, Shinshu University School of Medicine, Matsumoto, Japan.
Cook
D A
DA
Weir
B K
BK
Handa
Y
Y
D000255:Adenosine Triphosphate / Q000494:pharmacology; D000818:Animals; D002536:Cerebral Arteries / Q000187:drug effects* / Q000502:physiology; D015237:Dinoprost / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006454:Hemoglobins / Q000494:pharmacology; D002546:Ischemic Attack, Transient / Q000503:physiopathology / Q000517:prevention & control*; D008252:Macaca fascicularis; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000502:physiology; D009638:Norepinephrine / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D012701:Serotonin / Q000494:pharmacology; D013345:Subarachnoid Hemorrhage / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors; D014661:Vasoconstriction / Q000187:drug effects
D006454:Hemoglobins; D012701:Serotonin; D011189:Potassium Chloride; D000255:Adenosine Triphosphate; D015237:Dinoprost; D009638:Norepinephrine